Literature DB >> 22378254

Advancing the development of tuberculosis therapy.

Alimuddin Zumla1, Richard Hafner, Christian Lienhardt, Michael Hoelscher, Andrew Nunn.   

Abstract

Although the development of novel drugs and combination regimens for tuberculosis has accelerated in recent years, the pipeline remains thin and major challenges remain to be addressed in efficiently evaluating newer drugs to improve treatment outcomes, shorten duration of therapy and tackle drug resistance.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22378254     DOI： 10.1038/nrd3694

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  2 in total

1.  Innovative trial designs are practical solutions for improving the treatment of tuberculosis.

Authors:  Patrick P J Phillips; Stephen H Gillespie; Martin Boeree; Norbert Heinrich; Rob Aarnoutse; Tim McHugh; Michel Pletschette; Christian Lienhardt; Richard Hafner; Charles Mgone; Alimuddin Zumla; Andrew J Nunn; Michael Hoelscher
Journal:  J Infect Dis       Date:  2012-03-22       Impact factor: 5.226

Review 2.  Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis.

Authors:  Evan W Orenstein; Sanjay Basu; N Sarita Shah; Jason R Andrews; Gerald H Friedland; Anthony P Moll; Neel R Gandhi; Alison P Galvani
Journal:  Lancet Infect Dis       Date:  2009-03       Impact factor: 25.071
  2 in total
  21 in total

1.  Double recombinant Mycobacterium bovis BCG strain for screening of primary and rationale-based antimycobacterial compounds.

Authors:  Vandana Singh; Rajesh Kumar Biswas; Bhupendra N Singh
Journal:  Antimicrob Agents Chemother       Date:  2013-12-16       Impact factor: 5.191

2.  Beauvericin Potentiates Azole Activity via Inhibition of Multidrug Efflux, Blocks Candida albicans Morphogenesis, and Is Effluxed via Yor1 and Circuitry Controlled by Zcf29.

Authors:  Tanvi Shekhar-Guturja; Walters Aji Tebung; Harley Mount; Ningning Liu; Julia R Köhler; Malcolm Whiteway; Leah E Cowen
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

3.  Influence of vehicles used for oral dosing of test molecules on the progression of Mycobacterium tuberculosis infection in mice.

Authors:  Shubhra Singh; Richa Dwivedi; Vinita Chaturvedi
Journal:  Antimicrob Agents Chemother       Date:  2012-08-27       Impact factor: 5.191

4.  Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors.

Authors:  Sarah M Batt; Talat Jabeen; Veemal Bhowruth; Lee Quill; Peter A Lund; Lothar Eggeling; Luke J Alderwick; Klaus Fütterer; Gurdyal S Besra
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-25       Impact factor: 11.205

Review 5.  Combinatorial strategies for combating invasive fungal infections.

Authors:  Michaela Spitzer; Nicole Robbins; Gerard D Wright
Journal:  Virulence       Date:  2016-06-07       Impact factor: 5.882

6.  Serum biomarkers of treatment response within a randomized clinical trial for pulmonary tuberculosis.

Authors:  A Jayakumar; E Vittinghoff; M R Segal; W R MacKenzie; J L Johnson; P Gitta; J Saukkonen; J Anderson; M Weiner; M Engle; C Yoon; M Kato-Maeda; P Nahid
Journal:  Tuberculosis (Edinb)       Date:  2015-05-09       Impact factor: 3.131

Review 7.  The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis.

Authors:  Borna Müller; Sonia Borrell; Graham Rose; Sebastien Gagneux
Journal:  Trends Genet       Date:  2012-12-13       Impact factor: 11.639

8.  Novel Cell-Killing Mechanisms of Hydroxyurea and the Implication toward Combination Therapy for the Treatment of Fungal Infections.

Authors:  Amanpreet Singh; Ameeta Agarwal; Yong-Jie Xu
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

9.  Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis.

Authors:  V Balasubramanian; S Solapure; H Iyer; A Ghosh; S Sharma; P Kaur; R Deepthi; V Subbulakshmi; V Ramya; V Ramachandran; M Balganesh; L Wright; D Melnick; S L Butler; V K Sambandamurthy
Journal:  Antimicrob Agents Chemother       Date:  2013-11-04       Impact factor: 5.191

10.  The Extracellular Matrix Regulates Granuloma Necrosis in Tuberculosis.

Authors:  Basim Al Shammari; Takayuki Shiomi; Liku Tezera; Magdalena K Bielecka; Victoria Workman; Tarangini Sathyamoorthy; Francesco Mauri; Suwan N Jayasinghe; Brian D Robertson; Jeanine D'Armiento; Jon S Friedland; Paul T Elkington
Journal:  J Infect Dis       Date:  2015-02-12       Impact factor: 5.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.